KONEXElectronic Components336040

Tascom

₩3,500 0.00%2026-11-18 close
Market Cap
₩20.3B
Turnover
₩0
Volume
0 shares
Shares out.
5.8M
PER
—
PBR
—
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Capital erosion amid a diagnostics pivot

Tascom is a KONEX-listed company where revenue decline and full capital impairment are unfolding alongside a narrowing of its business toward in-vitro diagnostic devices.

  1. 1

    On a separate basis for 2025, the operating loss and net loss amounted to a large share of revenue, so whether sales recover is the point that decides the size of the loss.

  2. 2

    Total equity stood at negative 1,180 million KRW in the same period, leaving the company in full capital impairment with liabilities exceeding assets.

  3. 3

    Consolidated revenue fell from 10.3 billion KRW in 2021 to 6.5 billion KRW in 2024, while the 2024 operating margin of -22.98 percent was narrower than the -51.57 percent recorded in 2023.

  4. 4

    With sales of penneedles and syringes discontinued, in-vitro diagnostic devices are shifting to the center of the business.

  5. 5

    A third-party allotment rights issue decided at the end of 2025 is set to raise about 2 billion KRW for working capital and debt repayment.

02

Business structure

Tascom develops and sells in-vitro diagnostic medical devices and was listed on the KONEX market on December 2, 2019. Its current business structure took shape after Yidobio absorbed Tascom, a point-of-care diagnostic device maker, and the combined entity adopted the Tascom name.

The core product, SIMPLEXTAS 101, runs tests on a small blood sample at the point of care and is positioned on its ability to work outside hospitals. According to reporting at the time, the company sold point-of-care diagnostic devices in 14 countries including in Europe and South America.

The business rests on two pillars: point-of-care device sales and cell therapy research for type 1 diabetes using induced pluripotent stem cells.

Penneedle and syringe products, which once accounted for a large share of revenue, were discontinued after a sales agreement with Becton Dickinson Korea ended, and the company described the move as part of a push to concentrate on its diagnostics business.

The in-vitro diagnostics market is described as growing on demand from an aging population and rising chronic disease, with a shift toward diagnosis and prevention. Still, revenue remains in the tens of billions of KRW range, which limits direct comparison with large diagnostics companies.

Listed peers in the same sector such as InBody, which handles measurement and diagnostic equipment, can serve as a more practical benchmark.

03

Recent trends

On separate financial statements for 2025, revenue was 2,311 million KRW, operating loss was 1,767 million KRW, and net loss was 1,699 million KRW. Total assets were 2,154 million KRW and total liabilities were 3,334 million KRW in the same period, leaving equity negative and the company in full capital impairment.

Consolidated revenue declined for four consecutive years, from 10.3 billion KRW in 2021 to 9.0 billion KRW in 2022, 7.8 billion KRW in 2023, and 6.5 billion KRW in 2024. The 2024 operating margin of -22.98 percent was narrower than the -51.57 percent recorded in 2023.

At the end of 2025 the board decided on a third-party allotment rights issue of 740,740 new shares at 2,700 KRW per share, raising about 2 billion KRW. The proceeds are designated for 1.4 billion KRW of working capital and 600 million KRW of debt repayment, with payment scheduled for January 22, 2026.

At the March 26, 2026 shareholder meeting, the agenda approving the 12th fiscal year financial statements passed, with 50.4 percent approval of total issued voting shares. A disclosure dated April 9, 2026 reported that Smilegate Investment's stake fell to 11.31 percent.

As of April 30, 2026, major shareholder KAI-Tyon Unicorn Fund No. 9 held 10.96 percent. Based on market data, the 52-week high was 5,280 KRW and the low was 1,800 KRW, and the current share price is 3,500 KRW.

04

Outlook

The business has narrowed toward in-vitro diagnostic devices, and future results will depend on whether point-of-care device sales recover. After the penneedle and syringe revenue dropped out, the key question is how far expanding SIMPLEXTAS 101 sales countries and adding new test items can fill the revenue gap.

Whether the margin improvement seen in 2024 continues after 2025 can be tracked through quarterly disclosures. On the capital side, the rights issue proceeds earmarked for working capital and debt repayment may ease near-term liquidity pressure.

However, with equity still negative, how the rights issue effect and 2026 earnings flow into total equity is the next checkpoint. The company said in 2022 reporting that it was pursuing a transfer listing to KOSDAQ and targeted a clinical trial filing for its type 1 diabetes cell therapy.

Disclosures on the KOSDAQ transfer and progress in the cell therapy pipeline will shape how the business direction is read. At the sector level, an aging population and rising chronic disease are cited as structural drivers of in-vitro diagnostic demand.

05

Bull factors

Structural demand for diagnostics

FnGuide's company summary notes that a shift from treatment toward diagnosis and prevention, driven by an aging population and rising chronic disease, is expected to support sustained growth in the in-vitro diagnostics market. Tascom has built its core product around point-of-care testing from a small blood sample. The ability to test without a hospital visit has been presented as its key differentiator.

An overseas point-of-care sales base

According to Edaily reporting at the time, Tascom sold point-of-care diagnostic devices in 14 countries including in Europe and South America. The company said it was preparing to sell SIMPLEXTAS 101 in more countries and to add test items matched to market demand, such as a COVID-19 neutralizing antibody test. Whether this overseas base can anchor a revenue recovery will be judged through product-level sales trends.

Shareholder base and funding flow

As of April 30, 2026, KAI-Tyon Unicorn Fund No. 9 is listed as a major shareholder, which points to a shareholder base centered on financial investors. A disclosure dated April 9, 2026 reported that Smilegate Investment's stake fell to 11.31 percent.

The late-2025 third-party allotment drew participation from existing and new financial investors, providing funds for working capital and debt repayment.

Continued investor participation in financing can be read as supportive for financial stability, though the reasons behind stake changes cannot be determined from disclosures alone.

06

Bear factors

Full capital impairment and debt burden

On separate financial statements for 2025, total equity was negative 1,180 million KRW, placing the company in full capital impairment. Total liabilities of 3,334 million KRW exceed total assets of 2,154 million KRW. Because of this structure, the need for additional funding remains a central weakness.

Shrinking revenue and persistent operating losses

Consolidated revenue fell from 10.3 billion KRW in 2021 to 6.5 billion KRW in 2024, and separate revenue dropped further to 2,311 million KRW in 2025. The 2025 operating loss of 1,767 million KRW is large relative to revenue. Although the 2024 operating margin improved to -22.98 percent, the company remained in a loss-making structure.

Discontinued core product sales

After a sales agreement with Becton Dickinson Korea ended, the board decided to halt sales of penneedles and syringes. These items had accounted for the largest share of half-year revenue.

The company described the move as part of a strategy to focus on diagnostics devices, but in the short term it reduces the revenue base.

07

Risk factors

Macro

If high interest rates and an economic slowdown persist, medical device purchasing budgets may shrink and funding conditions for small and mid-sized listed companies may worsen. The 52-week price range of 1,800 KRW to 5,280 KRW shows substantial share price volatility for a small KONEX-listed stock. Exchange rates and import conditions in overseas sales markets could also affect profitability.

Regulatory

In-vitro diagnostic devices must clear country-specific approval procedures before sale, so the pace of expanding sales countries depends on regulatory timelines. Adding new test items also requires approval.

The clinical trial filing target for the type 1 diabetes cell therapy, reported in 2022, may also shift depending on regulatory review and research progress.

Capital and liquidity

The late-2025 rights issue added 740,740 new shares, diluting existing shareholders. If full capital impairment is not resolved, the company may need to meet additional requirements to maintain its listing and pursue a transfer to KOSDAQ.

The KOSDAQ transfer plan reported in 2022 may have changed in timing and requirements, which will need to be confirmed through disclosures.

08

Overall view

Tascom is a KONEX-listed company in the process of refocusing its business on in-vitro diagnostic devices. Separate-basis revenue declined and operating losses continued through 2025, and total equity turned negative, leaving the company in full capital impairment.

The late-2025 rights issue provided funds for working capital and debt repayment, but whether the capital structure has fundamentally improved is still too early to judge.

On the other side, the point-of-care device with small-sample testing, the overseas sales base, and the narrower loss margin in 2024 are presented as supportive factors. The discontinued penneedle and syringe sales reduced the near-term revenue base, although the company frames this as part of its diagnostics focus.

Strengths and weaknesses coexist, and how the rights issue effect and 2026 earnings flow into total equity is the next checkpoint.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 10 more articles and sources
  1. news.nate.com
  2. news.nate.com
  3. m.news.nate.com
  4. digitaltoday.co.kr
  5. comp.fnguide.com
  6. prestocknews.com
  7. prestocknews.com
  8. mpharm.edaily.co.kr
  9. dailymedi.com
  10. markets.hankyung.com

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis